A Clinical Protocol to evaluate the role of lysophosphatidic acid as
an aid in the differential diagnosis of ovarian cancer
in women scheduled for surgery

Zimmer Keila Valdwith a pelvic mass or a suspected ovarian malignancy.
Protocol Number:   ATG #8000
Date:  
 May 12, 2000

Version:  

 V.2
A Protocol to characterize lysophosphatidic acid assay levels

in women not suspected of ovarian cancer.
Protocol Number:   ATG #8001
Date:  
 May 12, 2000

Version:  

 V.2

Clinical Trials
Clinical Site Principal Investigator
Cedars-Sinai Medical CenterLille hotel rooms, Los Angeles, CA Beth Karlan, M.D.
Cleveland Clinic Foundation, Cleveland, OH Jerome Belinson, M.D.
Gynecologic Oncology Associates, Newport Beach, CA John Paul Micha, M.D.
M.D. Anderson Cancer Center, Houston, TX David Gershenson, M.D.
Northwestern University – Prentice Women’s Hospital, Chicago, IL David Fishman, M.D.
University of California, Davis, CA Gary S. Leiserowitz, M.D.
University of California, San Francisco, CA C. Bethan Powell, M.D.
University of Toronto, Sunnybrook Regional Cancer Center Allan Covens, M.D.
University of Toronto, Sunnybrook Women’s Health Sciences Center Patricia Shaw, M.D.

Untitled Document | Atairgin Useful Links | Atairgin Technologies, In | Atairgin Technologies, In | Untitled Document | Atairgin Technologies, In | Atairgin Press Release: M | Atairgin Technologies | Untitled Document | Untitled Document | Atairgin's Technology | Atairgin | Atairgin Technologies, In | Gordon B. Mills M.D., Ph. | Other Information | Atairgin Technologies -Ho | Atairgin Press Release: M | Targeted Diseases-Ovarian | Untitled Document | Welcome to Adobe GoLive 5 |